Hector F. DeLuca,Lori A. Plum,Margaret Clagett-Dame
申请号：
US14710744
公开号：
US20160184327A1
申请日:
2015.05.13
申请国别(地区):
US
年份:
2016
代理人:
摘要：
Disclosed are methods of administering 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D3 to treat primary hyperparathyroidism and/or to treat and/or prevent the symptoms of primary hyperparathyroidism in as subject having or at risk for developing primary hyperparathyroidism, preferably without inducing hypercalcemia in the patient
